Response to tilting in hypertensive patients receiving ketanserin
β Scribed by L. A. Ferrara; F. Pasanisi; M. L. Fasano; S. Soro
- Publisher
- Springer
- Year
- 1986
- Tongue
- English
- Weight
- 131 KB
- Volume
- 31
- Category
- Article
- ISSN
- 0031-6970
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Ketanserin, a serotonin antagonist, is effective in lowering portal pressure in a rat model of portal hypertension. As ketanserin has al-adrenoceptor-blocking properties in addition to its serotonin-blocking effects, we sought to define further the mechanism of ketanserin's portal pressure-lowering
Ketanserin, a 5-hydroxytryptamine-2 receptor blocker, has been shown to decrease portal pressure in recent acute hemodynamic studies that have been performed both in experimental animals and portal hypertensive patients. The present study was designed to investigate the effects of chronic oral admin
## Abstract Twelve scleroderma patients with hypertension, seven of whom had malignant hypertension and renal failure or scleroderma renal crisis, were treated with captopril. The first dose lowered mean pressure in all patients by 21.3 mmHg; in 6 patients it relieved encephalopathy. Blood pressure
## Abstract In a prospective study of 21 hypertensive patients receiving hydralazine for 1 year, we found a close relationship between development of antibodies to deoxyribonucleoprotein (DNP) and to hydralazine but no evidence for crossβreactivity between antibodies to these two antigens. Of 8 pat